19 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 19 of 19 clinical reviews.
A clinician-level guide to using compounded low-dose naltrexone (LDN) after bariatric surgery, covering altered pharmacokinetics, dosing strategies, safety data, and current clinical evidence.
An evidence-based breakdown of how low-dose naltrexone (LDN) affects cognitive function, brain fog, neuroinflammation, and mental clarity, including trial data, mechanisms, dosing, and clinical context.
A guide to how low-dose naltrexone (LDN) affects liver enzymes and hepatic safety, covering clinical trial data, FDA labeling, monitoring protocols, and who should avoid LDN entirely.
Does low-dose naltrexone change REM or deep sleep? A source-grounded review of the human evidence, vivid dreams, insomnia, timing, opioid interactions, and evidence gaps.
An evidence-based look at how low-dose naltrexone (LDN) affects bone density, osteoclast activity, and fracture risk, with primary-literature citations throughout.
A clinician-level review of the evidence on low-dose naltrexone (LDN) and cancer risk, covering proposed mechanisms, human trial data, preclinical findings, and practical prescribing considerations.
A comprehensive analysis of low-dose naltrexone (LDN) and its long-term cardiovascular effects, covering mechanistic data, clinical trials, safety signals, and prescribing guidance for telehealth clinicians.
A guide to low-dose naltrexone (LDN) for autoimmune conditions, covering mechanisms, clinical trial data, dosing, safety, and who may benefit.
A guide to how low-dose naltrexone (LDN) affects hair growth, hair loss, skin inflammation, and dermatologic autoimmune conditions, with primary-literature citations and dosing context.
How low-dose naltrexone (LDN), typically 1.5 to 4.5 mg, may affect depression, anxiety, and mood, with an honest read of the trial evidence, mechanisms, dosing considerations, and safety limits.
How low-dose naltrexone (LDN) may support muscle preservation through glial modulation, cytokine reduction, and IGF-1 pathway effects. MD/PharmD-level review with primary literature, dosing guidance, and a decision framework.
How long before surgery should you stop low-dose naltrexone? This MD/PharmD-level guide covers the evidence-based hold window, opioid-antagonism pharmacokinetics, anesthesia risks, and restart timing after your procedure.
Does stopping low-dose naltrexone cause rebound pain, inflammation, or withdrawal? A deep dive into the pharmacology, trial data, and tapering protocols for LDN discontinuation.
A clinician-level guide to adjusting low-dose naltrexone (LDN) dosing, timing, and monitoring across seasons, covering winter immune shifts, summer heat effects, and condition-specific seasonal flare patterns.
A guide to adjusting compounded low-dose naltrexone (LDN) dosing times during air travel, crossing multiple time zones, and managing circadian disruption without losing therapeutic benefit.
A guide to how low-dose naltrexone (LDN) affects appetite, food cravings, and body weight, with primary-literature citations, dosing context, and practical guidance.
Compare compounded low-dose naltrexone with FDA-approved 50 mg naltrexone tablets and extended-release injection, including evidence limits, formulation differences, opioid interactions, and questions to ask a prescriber or pharmacy.
A clinician-level guide to safely restarting compounded low-dose naltrexone (LDN) after an acute illness, including when to pause, how to re-titrate, and what the evidence says about opioid receptor modulation and immune function.
A week-by-week clinical guide to low-dose naltrexone (LDN), covering dose titration, sleep changes, immune effects, and what the evidence says about fibromyalgia, autoimmune conditions, and inflammation during your first 30 days.